A newly approved protein-shredding drug gives myeloma patients another option

A newly approved cancer drug takes an unusual approach to treating multiple myeloma: instead of blocking a harmful protein, it marks the protein for destruction and lets the cell’s own disposal machinery shred it. The medicine, sold as Zenbexus, is the first of its kind cleared for this blood cancer.

Multiple myeloma is a cancer of plasma cells in the bone marrow, and while treatment has improved dramatically, the disease almost always returns after initial therapy. Each new mechanism of action gives patients and doctors another lever to pull when the cancer comes back.

How targeted protein degradation works

Zenbexus, whose active ingredient is iberdomide, belongs to an emerging class known as targeted protein degraders. Rather than merely inhibiting a disease-driving protein, these drugs harness the cell’s built-in recycling system to eliminate it entirely. The molecule binds to cereblon, a component of an enzyme complex that attaches a molecular tag to proteins slated for disposal. Once tagged, the target proteins are hauled off and broken down, according to the company’s announcement from Bristol Myers Squibb.

The proteins it eliminates

The drug directs the destruction of two proteins called Ikaros and Aiolos, which myeloma cells depend on to survive and multiply. By binding the cereblon pocket far more tightly than older drugs in the same family, iberdomide is engineered to recruit and degrade those targets more effectively. Removing the proteins the cancer relies on starves the malignant plasma cells, a strategy that differs from the checkpoint inhibitors and antibody drugs that dominate other corners of cancer care.

Targeted protein degradation has become one of the most closely watched frontiers in drug development. For decades, medicine chemists concentrated on inhibitors that block a protein’s activity, but many disease-driving proteins have no obvious pocket for a drug to latch onto, earning them the label undruggable. Degraders sidestep that problem by tagging the protein for removal rather than trying to switch it off, which opens the door to targets once considered out of reach. The approval of a degrader for myeloma is a concrete demonstration that the concept can move from the laboratory into approved therapy.

Who the approval covers

The Food and Drug Administration granted accelerated approval for Zenbexus in adults who have received at least one prior line of therapy, meaning it can be used as early as the first relapse rather than being reserved for heavily pretreated patients. It is intended to be given alongside daratumumab, delivered with hyaluronidase, and the steroid dexamethasone, a combination already familiar in myeloma treatment. Positioning the drug earlier in the disease course could bring its benefit to patients before they exhaust other options, as reflected in coverage aggregated by Drugs.com.

Why a first relapse matters

In multiple myeloma, the first relapse is a pivotal moment. Front-line treatment can drive the cancer into remission, but when it returns, the choice of the next regimen shapes how long a patient can be kept stable. Adding an effective new mechanism at that stage expands the sequence of therapies available and may delay the point at which the disease becomes resistant to everything on hand. A drug that attacks myeloma cells by degrading their essential proteins offers a distinct line of attack that does not overlap with every prior treatment.

The meaning of accelerated approval

The clearance came through the accelerated approval pathway, which allows a drug to reach patients based on early measures of benefit while longer-term confirmatory trials continue. For a cancer as serious and as prone to relapse as myeloma, that route can shorten the wait for new options. It also means the drug’s continued approval may depend on follow-up studies confirming that it improves outcomes over time, so its long-term role will be clarified as more data accumulate.

Where it fits among myeloma therapies

Multiple myeloma care already draws on immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, and cell-based therapies, and patients typically move through several regimens over the course of the disease. As the first cereblon-modulating protein degrader approved for the condition, Zenbexus adds a new category to that lineup. For physicians managing a cancer that repeatedly finds ways around treatment, having a therapy that works by demolishing the proteins myeloma cells need is a meaningful addition to an increasingly deep set of choices.

Survival in multiple myeloma has climbed markedly over the past two decades, driven largely by the steady arrival of new drug classes that can be layered and sequenced as the disease evolves. Because myeloma cells are genetically diverse and adept at developing resistance, no single treatment holds them in check forever, and the practical value of a new agent often lies in offering a fresh mechanism that the cancer has not yet learned to evade. A protein degrader delivered in combination with an antibody and a steroid gives clinicians another distinct regimen to deploy at a critical juncture in that long campaign.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview